title: Anti-thrombin action of low-dose acetylsalicylic acid.
abstract: It is known that low-dose aspirin is effective in coronary artery therapy, although it has not yet been clarified how it exerts its action. Here, we report that treatment of coronary artery patients with 100 mg/day of aspirin does not attenuate thrombin generation, but reduces free thrombin by favouring the formation of thrombin/antithrombin (TAT) complexes. Antithrombin hyperactivation is mediated by inhibition of platelet factor 4 release from alpha-granules, leading to higher heparin availability.
authors.affiliation: Facoltà di Scienze MM.FF.NN, Università del Sannio, 82100 Benevento, Italy.
authors.forename: Biagio
authors.initials: B
authors.lastname: Di Micco
authors.forename: Giovanni
authors.initials: G
authors.lastname: Colonna
authors.forename: Pierpaolo
authors.initials: P
authors.lastname: Di Micco
authors.forename: Gianluca
authors.initials: G
authors.lastname: Di Micco
authors.forename: Bianca Maria
authors.initials: BM
authors.lastname: Russo
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Macalello
authors.forename: Raffaele
authors.initials: R
authors.lastname: Ragone
mesh_terms: D000368:Aged; D000990:Antithrombin III; D001241:Aspirin / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000097:blood*
chemical_list: D005343:Fibrinolytic Agents; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D001241:Aspirin